New Product is the Only FDA-Cleared Wound Debridement and Cleansing Solution Containing CHG; Offers Distinct Benefits
ATLANTA--(BUSINESS WIRE)-- Association of periOperative Registered Nurses (AORN) members attending the 58th Annual Congress will be among the first in the nation to be introduced to IrriSept® O.R. (www.irrisept.com), the first and only FDA-cleared wound debridement and cleansing system containing chlorhexidine gluconate (CHG). The 0.05 percent CHG concentration in IrriSept has been shown effective in laboratory testing against a variety of bacteria and fungi, including Staph and methicillin-resistant Staphylococcus aureus (MRSA).1,2 The solution has passed FDA-required tests for cytotoxicity, skin irritation and immune (allergic) response.3
Instead of cleansing a wound with just normal saline, health care providers can now apply IrriSept O.R. with CHG directly to a variety of wounds such as surgical wounds, delayed closures, SSTIs including abscesses, deep wounds, dehiscence, pilonidal cysts and burns. This surgical product includes a choice of three irrigation applicators: the original SplatterGuard® and the LT SplatterGuard®, that provide splatter protection and decrease aerosolized contamination during wound cleansing and debridement procedures, as well as the IrriProbe™ which is specifically designed for deeper wound cleansing in an operating room setting.
“The 2011 AORN Congress provides a tremendous opportunity for us to showcase IrriSept O.R.,” says IrriMax Chief Executive Officer Gareth Clarke, formerly the driving force behind the global expansion of Biogel® gloves. “Because surgical site infections are a major concern for AORN members, we are eager to introduce health care providers to the merits of the IrriSept system, knowing they will recognize its distinct benefits. Clarke adds, “I believe this new product has the potential to improve patient outcomes, decrease hospital lengths of stay and help medical facilities address infection-related challenges.”
AORN is a professional association that empowers the OR nurse with education, standards of practice and peer networking. The AORN Congress is the largest education and networking conference of perioperative nurse professionals in the world, and the largest surgical products trade show in the U.S. This year’s event will be held March 18-24 in Philadelphia.
Founded in 1994, IrriMax Corporation develops and markets wound irrigation solutions using a patented, innovative delivery method that produces unmatched efficacy and safety. The medical device company’s goal is to improve patient outcomes by treating and preventing infections, as well as to increase the safety of healthcare workers. Its flagship product, IrriSept®, is the first FDA-cleared wound debridement and cleansing system containing CHG. Continual innovation and ongoing clinical research guide the development of IrriMax products. For more information, visit www.irrisept.com.
IrriSept®, IrriMax®, IrriRinse®, SplatterGuard® and IrriProbe™ are trademarks of Innovation Technologies, Inc., parent company of IrriMax Corporation.
1 Laboratory Testing Records per USP <51>, Antimicrobial Effectiveness Testing, on file at IrriMax Corporation
2 Laboratory Testing Records, “Chlorhexidine Gluconate (CHG) Bacterial Study Report,” on file at IrriMax Corporation
3 Biocompatibility compliance tests completed per FDA’s Blue Book Memorandum G95-1 and ISO 10993-1, Biological Evaluation of Medical Devices, on file at IrriMax Corporation
For IrriMax Corporation
Debra Patterson, 404-843-8786
KEYWORDS: United States North America Georgia Pennsylvania
INDUSTRY KEYWORDS: Surgery Health Biotechnology Hospitals Infectious Diseases Medical Devices FDA Medical Supplies Nursing